HealthDay: Is new clot-busting medication better treatment for stroke?
UC expert says encouraging early findings need further study
Researchers are studying if a new "clot-busting" drug might be safer than the current treatment for strokes caused by brain bleeds.
The drug, tenecteplase, is currently approved for treating heart attacks but has not received FDA approval as a stroke treatment.
Joseph Broderick, MD, professor in UC’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician, told HealthDay the new drug is easier to administer and is less costly than current standard treatments. However, early results showing its effectiveness in patient case studies need to be replicated in formalized clinical trials.
Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.